Tamoxifen-Dependent Induction of AGR2 Is Associated with
Increased Aggressiveness of Endometrial Cancer Cells.

J 2017

Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells.

HRSTKA, Roman, Ján PODHOREC, Rudolf NENUTIL, Lucia SOMMEROVÁ, Joanna Agnieszka OBACZ et. al.

Základní údaje

Originální název

Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells.

Autoři

HRSTKA, Roman, Ján PODHOREC, Rudolf NENUTIL, Lucia SOMMEROVÁ, Joanna Agnieszka OBACZ, Michal ĎURECH, Jakub FAKTOR, Pavel BOUCHAL, Hana SKOUPILOVÁ a Bořivoj VOJTĚŠEK

Vydání

Cancer Investigation, Marcel Dekker, 2017, 0735-7907

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.053

Organizační jednotka

Přírodovědecká fakulta

DOI

http://dx.doi.org/10.1080/07357907.2017.1309546

UT WoS

000401553900003

Klíčová slova anglicky

AGR2; Breast cancer; Endometrial cancer; Tamoxifen

Štítky

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 4. 2019 14:16, Mgr. Tereza Miškechová

Anotace

V originále

Tamoxifen treatment in breast cancer patients is associated with increased risk of endometrial malignancies. Significantly, higher AGR2 expression was found in endometrial cancers that developed in women previously treated with tamoxifen compared to those who had not been exposed to tamoxifen. An association of elevated AGR2 level with myometrial invasion occurrence and invasion depth was also found. In vitro analyses identified a stimulatory effect of AGR2 on cellular proliferation. Although adverse tamoxifen effects on endometrial cells remain elusive, our work identifies elevated AGR2 as a candidate tamoxifen-dependent mechanism of action responsible for increased incidence of endometrial cancer.

Návaznosti

GA17-05957S, projekt VaV

Název: Evaluace nových potenciálních cílů a inhibitorů pro blokování vývoje metastáz u luminálních A nádorů prsu

Investor: Grantová agentura ČR, Evaluace nových potenciálních cílů a inhibitorů pro blokování vývoje metastáz u luminálních A nádorů prsu

Citovat

HRSTKA, Roman, Ján PODHOREC, Rudolf NENUTIL, Lucia SOMMEROVÁ, Joanna Agnieszka OBACZ, Michal ĎURECH, Jakub FAKTOR, Pavel BOUCHAL, Hana SKOUPILOVÁ a Bořivoj VOJTĚŠEK. Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells. Cancer Investigation. Marcel Dekker, 2017, roč. 35, č. 5, s. 313-324. ISSN 0735-7907. Dostupné z: https://dx.doi.org/10.1080/07357907.2017.1309546.

@article{1390162,
   author = {Hrstka, Roman and Podhorec, Ján and Nenutil, Rudolf and Sommerová, Lucia and Obacz, Joanna Agnieszka and Ďurech, Michal and Faktor, Jakub and Bouchal, Pavel and Skoupilová, Hana and Vojtěšek, Bořivoj},
   article_number = {5},
   doi = {http://dx.doi.org/10.1080/07357907.2017.1309546},
   keywords = {AGR2; Breast cancer; Endometrial cancer; Tamoxifen},
   language = {eng},
   issn = {0735-7907},
   journal = {Cancer Investigation},
   note = {Nepřenášet do RIV. Afiliace všech autorů je jen na Masarykův onkologický ústav!},
   title = {Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells.},
   url = {http://dx.doi.org/10.1080/07357907.2017.1309546},
   volume = {35},
   year = {2017}
}

TY  - JOUR
ID  - 1390162
AU  - Hrstka, Roman - Podhorec, Ján - Nenutil, Rudolf - Sommerová, Lucia - Obacz, Joanna Agnieszka - Ďurech, Michal - Faktor, Jakub - Bouchal, Pavel - Skoupilová, Hana - Vojtěšek, Bořivoj
PY  - 2017
TI  - Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells.
JF  - Cancer Investigation
VL  - 35
IS  - 5
SP  - 313-324
EP  - 313-324
PB  - Marcel Dekker
SN  - 07357907
N1  - Nepřenášet do RIV. Afiliace všech autorů je jen na Masarykův onkologický ústav!
KW  - AGR2
KW  - Breast cancer
KW  - Endometrial cancer
KW  - Tamoxifen
UR  - http://dx.doi.org/10.1080/07357907.2017.1309546
L2  - http://dx.doi.org/10.1080/07357907.2017.1309546
N2  - Tamoxifen treatment in breast cancer patients is associated with increased risk of endometrial malignancies. Significantly, higher AGR2 expression was found in endometrial cancers that developed in women previously treated with tamoxifen compared to those who had not been exposed to tamoxifen. An association of elevated AGR2 level with myometrial invasion occurrence and invasion depth was also found. In vitro analyses identified a stimulatory effect of AGR2 on cellular proliferation. Although adverse tamoxifen effects on endometrial cells remain elusive, our work identifies elevated AGR2 as a candidate tamoxifen-dependent mechanism of action responsible for increased incidence of endometrial cancer.
ER  -

HRSTKA, Roman, Ján PODHOREC, Rudolf NENUTIL, Lucia SOMMEROVÁ, Joanna Agnieszka OBACZ, Michal ĎURECH, Jakub FAKTOR, Pavel BOUCHAL, Hana SKOUPILOVÁ a Bořivoj VOJTĚŠEK. Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells. \textit{Cancer Investigation}. Marcel Dekker, 2017, roč.~35, č.~5, s.~313-324. ISSN~0735-7907. Dostupné z: https://dx.doi.org/10.1080/07357907.2017.1309546.

Podrobný výpis o publikaci